Egalet is a fully integrated specialty pharmaceutical company focused on developing and commercializing treatments for those living with pain.
seen from United States

seen from Malaysia
seen from China

seen from United States
seen from Aruba

seen from United States
seen from United States
seen from United States
seen from United States

seen from United States

seen from Italy
seen from China
seen from Sweden

seen from Malaysia
seen from China
seen from Canada

seen from Italy

seen from United States
seen from Canada
seen from Canada
Egalet is a fully integrated specialty pharmaceutical company focused on developing and commercializing treatments for those living with pain.
Egalet Corp (NASDAQ:EGLT) Gets Approval But Fails On Labelling, Here's What's Next
Egalet Corp (NASDAQ:EGLT) Gets Approval But Fails On Labelling, Here’s What’s Next
Here is an interesting one. We have covered Egalet Corp (NASDAQ:EGLT) on a number of occasions in the past here at Market Exclusive, with a specific focus on its abuse deterrent opioid application, which has been with the FDA for the better part of 12 months in its latest iteration. The company has repeatedly tried to get the asset approved and advanced into the commercialization phase, but has…
View On WordPress
Pretty much in heaven right now @whitedogwayne 😍Bubbles, 1000 paintings of puppies, and steak tartar 🙌🏻#wayne #egalet #whitedogcafewayne (at White Dog Cafe Wayne)
❤️ #philadelphia #egalet #6degrees #loveisloveislove
That time it was 12 degrees in Philadelphia 😳 #holidaze #thursYaY #egalet (at McGillin's Olde Ale House)
Our mannequin challenge failed on a number of levels 😂 #love #philadelphia #6degrees #thursYaY #egalet (at Christmas Village in Philadelphia)
Hood life 😍#egalet #thursYaY #itsfreezingoutside #philadephia #6degrees (at Philadelphia, Pennsylvania)
Is Egalet Corp (NASDAQ:EGLT) A Discount Entry On Its FDA Delay?
Is Egalet Corp (NASDAQ:EGLT) A Discount Entry On Its FDA Delay?
One thing we love to do here at Market Exclusive is to highlight potential discount entries in the biotech space. There is so much market inefficiency based around interpretation and misinterpretation of data releases and news updates, that these discount entries crop up quite regularly, and are there for the taking with the right timing. Of course, they don’t always play out, but when they do,…
View On WordPress